SAGIMET BIOSCIENCES INC-A (SGMT) Stock News

USA - Nasdaq - NASDAQ:SGMT - US7867001049 - Common Stock

7.08 USD

+0.1 (+1.43%)

Last: 11/26/2025, 8:03:21 PM

7.22 USD

+0.14 (+1.98%)

After Hours: 11/26/2025, 8:03:21 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

SGMT Latest News, Press Relases and Analysis

All

Press Releases

8 days ago - By: Sagimet Biosciences Inc.

Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference

8 days ago - By: Sagimet Biosciences Inc.

Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference

15 days ago - By: Sagimet Biosciences Inc.

Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

15 days ago - By: Sagimet Biosciences Inc.

Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

a month ago - By: Stocktwits - Mentions: VXF DFAU

News Image

Sagimet Biosciences Stock Soars After Positive Data For Experimental Drug In Acne Study

18 days ago - By: Sagimet Biosciences Inc.

Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting® 2025

a month ago - By: Sagimet Biosciences Inc.

Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference

a month ago - By: Sagimet Biosciences Inc.

Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference

a month ago - By: Benzinga - Mentions: FSLR V PYPL KVYO

This Visa Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

a month ago - By: Sagimet Biosciences Inc.

Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences

a month ago - By: Sagimet Biosciences Inc.

Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences

a month ago - By: Ascletis Pharma Inc.

News Image

Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration

2 months ago - By: Sagimet Biosciences Inc.

Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025

2 months ago - By: Sagimet Biosciences Inc.

Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025

2 months ago - By: Sagimet Biosciences Inc.

Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination

2 months ago - By: Sagimet Biosciences Inc.

Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination

2 months ago - By: Sagimet Biosciences Inc.

Sagimet Biosciences Announces Upcoming Panel Participation at Fierce Biotech Week

2 months ago - By: Sagimet Biosciences Inc.

Sagimet Biosciences Announces Upcoming Panel Participation at Fierce Biotech Week

2 months ago - By: Ascletis Pharma Inc.

News Image

Ascletis Presented Phase III Study Results of First-in-Class FASN Inhibitor Denifanstat (ASC40) for Acne Treatment in the Late Breaking News Sessions of the European Academy of Dermatology and Venereology (EADV) Congress 2025

2 months ago - By: Sagimet Biosciences Inc.

Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis

2 months ago - By: Sagimet Biosciences Inc.

Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis

3 months ago - By: Sagimet Biosciences Inc.

Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit

3 months ago - By: Sagimet Biosciences Inc.

Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit

3 months ago - By: Sagimet Biosciences Inc.

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

3 months ago - By: Sagimet Biosciences Inc.

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

3 months ago - By: Zacks Investment Research

Sagimet Biosciences Inc. (SGMT) Upgraded to Buy: What Does It Mean for the Stock?

3 months ago - By: Zacks Investment Research

After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)

4 months ago - By: The Motley Fool

Sagimet Biosciences Tops Q2 EPS Forecast

4 months ago - By: Sagimet Biosciences Inc.

Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

4 months ago - By: Sagimet Biosciences Inc.

Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

4 months ago - By: Sagimet Biosciences Inc.

Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

4 months ago - By: Sagimet Biosciences Inc.

Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

4 months ago - By: Benzinga - Mentions: ESLT SRPT BRZE EPRX

This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday

6 months ago - By: Yahoo Finance - Mentions: STRF

5 Ways Trump’s ‘Big, Beautiful Bill’ Could Impact Your Wallet

6 months ago - By: Sagimet Biosciences Inc.

Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025

6 months ago - By: Sagimet Biosciences Inc.

Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025